- Bob Hugin brings 20 years of experience in strategic growth and global expansion at a leading biopharmaceutical anticancer company.
- The Council is a group of goodwill ambassadors who provide strategic advice, assist with raising funds, and build awareness.
Bob previously served as the Chairman and Chief Executive Officer of Celgene Corporation, where he led the strategic growth and global expansion of the biopharmaceutical anticancer company for nearly 20 years. Celgene was ultimately acquired by Bristol-Myers Squibb in 2019.
The Foundation is pleased to welcome Bob Hugin to its Council, a dedicated group of goodwill ambassadors who work closely with the Board of Directors and staff to provide strategic advice and assist with building awareness, establishing relationships, and raising funds.
“We are pleased to welcome Bob among our exceptional group of Council members,” said Foundation Chairman Neal F. Kassell, MD. “His transformational leadership in the biopharmaceutical industry, deep knowledge, and global relationships will help the Foundation propel its vision of improving the lives of millions of people around the world with a variety of serious medical disorders. One of the Foundation’s central initiatives involves exploring the intersections between focused ultrasound and cancer immunotherapy, and Bob’s expertise in this space will be invaluable.”
Bob is currently a Director of the Parker Institute for Cancer Immunotherapy and Chair of The Darden School Foundation at the University of Virginia. He serves as a Director of Chubb Ltd. and Biohaven Pharmaceutical Holding Company Ltd. In the past five years, he also served as a Director of Allergan plc, Danaher Corporation, and The Medicines Company. Bob is past Chairman of the Boards of the Pharmaceutical Research and Manufacturers of America and the Healthcare Institute of New Jersey.
Continuing a tradition of public service that began with his college enlistment in the United States Marine Corps, Bob currently serves as Chair of the Board of the Garden State Initiative and the Board of Trustees of Family Promise.
Prior to joining Celgene, Bob was a Managing Director with J.P. Morgan & Co. Inc. The first in his family to attend college, Bob received an AB degree from Princeton University in 1976 and an MBA from the University of Virginia in 1985. He served as a Marine Corps infantry officer during the intervening period. “I am looking forward to being involved,” said Bob. “Focused ultrasound shows great promise for improving patients’ lives, and I am particularly committed to technologies that may transform treatment for multiple cancers.”